The global optic neuropathy management market is expected to garner a market value of US$ 4.3 Billion in 2023 and is expected to accumulate a market value of US$ 7 Billion by registering a CAGR of 5% in the forecast period 2023 to 2033. The market for Optic Neuropathy Management registered a CAGR of 3.2% in the historical period 2018 to 2022.
The optic neuropathy management market is a segment of the healthcare industry that is focused on developing and distributing medical products and services for the treatment and management of optic neuropathy. Optic neuropathy is a condition that affects the optic nerve, which is responsible for transmitting visual information from the eyes to the brain. This condition can result in vision loss, blurred vision, and other symptoms.
The optic neuropathy management market includes a variety of products and services, including medications, surgical procedures, and diagnostic tools. Some of the key players in this market include pharmaceutical companies, medical device manufacturers, and healthcare providers.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 4.3 billion |
| Anticipated Forecast Value (2033) | US$ 7 billion |
| Projected Growth Rate (2023 to 2033) | 5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider, Future Market Insights- the market for optic neuropathy management reflected a value CAGR of 3.2% during the historical period, 2018 to 2022. One of the major drivers of the optic neuropathy management market is the increasing prevalence of optic neuropathy, which is associated with a range of underlying medical conditions, including diabetes, multiple sclerosis, and glaucoma. Additionally, the aging population is also contributing to the growth of this market, as the risk of developing optic neuropathy increases with age.
Advancements in technology and research are leading to the development of new diagnostic tools and treatment options. For example, the development of gene therapy and other innovative treatments may provide new options for managing optic neuropathy. Additionally, the use of advanced imaging techniques such as optical coherence tomography (OCT) is enabling earlier diagnosis and more precise monitoring of optic neuropathy, which could lead to better outcomes for patients.
Furthermore, increasing awareness and education about optic neuropathy among patients and healthcare providers is also contributing to market growth. As more people become aware of the condition and its impact on vision, there is likely to be increased demand for early diagnosis and effective treatment. The market for optic neuropathy management is expected to register a CAGR of 5% in the forecast period 2023 to 2033.
Increasing Prevalence of Optic Neuropathy to push market growth
The increasing prevalence of optic neuropathy is expected to be one of the key drivers of market growth in the optic neuropathy management market. Optic neuropathy is a condition that affects the optic nerve, which transmits visual information from the eyes to the brain. The condition can result in vision loss, blurred vision, and other symptoms, and is associated with a range of underlying medical conditions, including diabetes, multiple sclerosis, and glaucoma.
The global prevalence of optic neuropathy is increasing, with estimates suggesting that the condition affects around 3% of the world's population. This is driving demand for new and innovative treatment options, as well as increasing the number of patients seeking care for the condition.
The rising incidence of underlying medical conditions such as diabetes and glaucoma is one of the main drivers of the increasing prevalence of optic neuropathy. Diabetes, for example, is a major risk factor for optic neuropathy, with diabetic retinopathy being a common cause of the condition. As the incidence of diabetes continues to rise globally, so too does the incidence of optic neuropathy.
Similarly, the incidence of glaucoma, which is another major cause of optic neuropathy, is also on the rise. Glaucoma is a group of eye diseases that can lead to damage of the optic nerve and is one of the leading causes of blindness worldwide.
Overall, the increasing prevalence of optic neuropathy is expected to drive significant growth in the optic neuropathy management market in the coming years. This presents opportunities for healthcare companies and providers to develop new and innovative solutions for managing the condition, as well as improving access to existing treatments and services.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
Despite advances in research and technology, there are still limited treatment options available for optic neuropathy. Many existing treatments focus on managing symptoms rather than addressing the underlying causes of the condition.
Optic neuropathy management can be costly, particularly for patients who require ongoing treatment and monitoring. This can make it difficult for patients to access the care they need, particularly in low- and middle-income countries.
Overall, addressing these challenges will be crucial to improving outcomes for patients with optic neuropathy and driving growth in the optic neuropathy management market. This will require a collaborative effort from healthcare providers, researchers, and policymakers to improve access to care, increase awareness and understanding of the condition, and develop new and innovative treatments and diagnostic tools.
Increasing awareness and diagnosis of the condition Shaping Landscape for Optic Neuropathy Management in South & East Asia
The optic neuropathy management market in the South & East Asia region is growing, driven by increasing prevalence of underlying medical conditions such as diabetes, glaucoma, and hypertension, which are the leading causes of optic neuropathy in the region. The market is also being fueled by the growing aging population and rising awareness about the condition and its management among healthcare providers and patients.
In addition, there is a growing trend towards the adoption of advanced technologies and treatments for optic neuropathy management in the region. This includes the use of advanced imaging techniques such as optical coherence tomography (OCT) and electroretinography (ERG) to improve diagnosis and monitoring of the condition.
However, the market also faces several challenges in the South & East Asia region. One of the main challenges is limited access to healthcare and diagnostic services, particularly in rural areas. This can lead to delays in diagnosis and treatment, which can result in further vision loss and other complications.
Another challenge is the high cost of treatments, which can make it difficult for many patients to access the care they need. This is particularly true in low- and middle-income countries, where access to healthcare is limited and the burden of chronic diseases such as diabetes is high.
Overall, the optic neuropathy management market in the South & East Asia region is expected to continue to grow in the coming years, driven by a range of factors including increasing prevalence of the condition and the adoption of advanced technologies and treatments. However, addressing the challenges facing the market will be crucial to improving outcomes for patients and ensuring sustainable growth in the region.
Increasing Focus on Technological Advancements Shaping Landscape for Optic Neuropathy Management in North America
The optic neuropathy management market in North America is expected to experience significant growth in the coming years, driven by several factors. One of the primary drivers of market growth is the high prevalence of underlying medical conditions that can lead to optic neuropathy, such as diabetes, multiple sclerosis, and glaucoma. These conditions are becoming increasingly common in North America, particularly among the aging population, and are contributing to a growing demand for innovative and effective treatments for optic neuropathy.
In addition to the increasing prevalence of underlying medical conditions, the market is also being fuelled by advances in technology and research. New diagnostic tools and treatment options are being developed, including gene therapies, stem cell therapies, and neuroprotective agents, which are expected to improve outcomes for patients with optic neuropathy.
Another key factor driving the optic neuropathy management market in North America is the high level of awareness and understanding of the condition among healthcare providers and the general public. This has led to increased diagnosis rates and better management of the condition, which is contributing to improved patient outcomes.
Finally, the presence of well-established healthcare infrastructure and a high level of investment in research and development in North America are also expected to boost market growth. This has created a favorable environment for the development and commercialization of new and innovative products and treatments for optic neuropathy.
Overall, the optic neuropathy management market in North America is poised for significant growth in the coming years, driven by a range of factors including increasing prevalence of underlying medical conditions, advances in technology and research, high levels of awareness and understanding, and a favorable healthcare infrastructure and investment environment. As per FMI, the North America market is slated to hold a revenue share of 40%.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Injectable route of administration to hold a significant share and push market growth
The injectable route of administration is likely to account for a significant share of the optic neuropathy management market. This is due to the effectiveness of parenteral treatments, which can be administered directly into the bloodstream or affected area for faster and more targeted delivery of medication.
Injectable treatments are also preferred in cases where oral medications may not be suitable, such as for patients with difficulty swallowing or those who require higher doses that may not be feasible with oral medications. In addition, several established parenteral treatments for optic neuropathy are already available on the market, which further contributes to the dominance of the injectable segment.
Hospital pharmacies segment to hold a significant share and push market growth
Hospitals and specialty clinics are often the first point of contact for patients with optic neuropathy, as they provide specialized care and access to diagnostic tools and treatments. These facilities also have the expertise and resources to provide comprehensive care to patients with complex or severe cases of optic neuropathy.
In addition, many of the treatments for optic neuropathy require specialized administration or monitoring, such as intravitreal injections or electroretinography testing, which are typically performed in hospitals or specialty clinics. This further contributes to the dominance of these distribution channels in the optic neuropathy management market.
Overall, hospitals and specialty clinics are likely to continue to account for a significant share of the optic neuropathy management market, driven by the specialized care and expertise they provide. However, as patient preferences and healthcare delivery models continue to evolve, the market share of the various distribution channels may shift over time.
Key players in the market include companies such as AbbVie Inc., Eli Lily Company, GlaxoSmithKline, Pfizer Inc., Teva Pharmaceuticals, Bausch Health Companies Inc., F. Hoffmann-La Roche AG, Bayer AG, Sanofi A.S., Bristol-Myers Squibb and Company, along with healthcare providers and technology companies among other global players.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 4.3 Billion |
| Market Value in 2033 | USD 7 Billion |
| Growth Rate | CAGR of 5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Route of Administration, Distribution Channel, Drug Class, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | AbbVie Inc.; Eli Lilly and Company; GSK Plc.; Pfizer Inc.; Teva Pharmaceutical Industries Ltd.; Bausch Health Companies Inc.; F. Hoffmann-La Roche AG; Bayer AG; Sanofi S.A; Bristol-Myers Squibb Company |
| Customization | Available Upon Request |
The global market value is estimated to be near US$ 4.3 billion in 2023.
The injectable route of administration is expected to remain the preferred choice during the forecast years.
A higher prevalence of underlying medical conditions makes North America the leading market.
The regional markets in South & East Asia are expected to follow a higher growth rate through 2033.
The availability of limited treatment options remains a significant challenge for market players.
1. Executive Summary | Optic Neuropathy Management Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Corticosteroids 5.3.2. Antimetabolites 5.3.3. Anticoagulants 5.3.4. Serotonin and norepinephrine reuptake inhibitors 5.3.5. Nonsteroidal Anti-Inflammatory Drugs 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 6.3.1. Oral 6.3.2. Injectable 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 7.3.1. Hospital Pharmacies 7.3.2. Retail Pharmacies 7.3.3. Online Pharmacies 7.3.4. Drug Stores 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. Middle East & Africa 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. United States 9.2.1.2. Canada 9.2.2. By Drug Class 9.2.3. By Route of Administration 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Class 9.3.3. By Route of Administration 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Class 10.2.3. By Route of Administration 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Route of Administration 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Drug Class 11.2.3. By Route of Administration 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Route of Administration 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Drug Class 12.2.3. By Route of Administration 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Route of Administration 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Drug Class 13.2.3. By Route of Administration 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Route of Administration 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Drug Class 14.2.3. By Route of Administration 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Route of Administration 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Drug Class 15.2.3. By Route of Administration 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By Route of Administration 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. U.S. 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Drug Class 16.1.2.2. By Route of Administration 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Drug Class 16.2.2.2. By Route of Administration 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Drug Class 16.3.2.2. By Route of Administration 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Drug Class 16.4.2.2. By Route of Administration 16.4.2.3. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Drug Class 16.5.2.2. By Route of Administration 16.5.2.3. By Distribution Channel 16.6. U.K. 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Drug Class 16.6.2.2. By Route of Administration 16.6.2.3. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Drug Class 16.7.2.2. By Route of Administration 16.7.2.3. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Drug Class 16.8.2.2. By Route of Administration 16.8.2.3. By Distribution Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Drug Class 16.9.2.2. By Route of Administration 16.9.2.3. By Distribution Channel 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Drug Class 16.10.2.2. By Route of Administration 16.10.2.3. By Distribution Channel 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Drug Class 16.11.2.2. By Route of Administration 16.11.2.3. By Distribution Channel 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Drug Class 16.12.2.2. By Route of Administration 16.12.2.3. By Distribution Channel 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Drug Class 16.13.2.2. By Route of Administration 16.13.2.3. By Distribution Channel 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Drug Class 16.14.2.2. By Route of Administration 16.14.2.3. By Distribution Channel 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Drug Class 16.15.2.2. By Route of Administration 16.15.2.3. By Distribution Channel 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Drug Class 16.16.2.2. By Route of Administration 16.16.2.3. By Distribution Channel 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Drug Class 16.17.2.2. By Route of Administration 16.17.2.3. By Distribution Channel 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Drug Class 16.18.2.2. By Route of Administration 16.18.2.3. By Distribution Channel 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Drug Class 16.19.2.2. By Route of Administration 16.19.2.3. By Distribution Channel 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Drug Class 16.20.2.2. By Route of Administration 16.20.2.3. By Distribution Channel 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Drug Class 16.21.2.2. By Route of Administration 16.21.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug Class 17.3.3. By Route of Administration 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. AbbVie Inc. 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Eli Lilly and Company 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. GSK Plc. 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Pfizer Inc. 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Teva Pharmaceutical Industries Ltd. 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Bausch Health Companies Inc. 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. F. Hoffmann-La Roche AG 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Bayer AG 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. Sanofi S.A. 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Bristol-Myers Squibb Company 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Optic Neuropathy Management Market
